{"title":"东印度视神经脊髓炎患者的研究","authors":"Soumava Mukherjee, Gautam Guha, Manoj Roy, Sinjan Ghosh, Shankar Prasad Saha","doi":"10.1016/j.npbr.2019.12.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>To study the clinical presentation and response to immunosuppressives in patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) in a tertiary care hospital of eastern India.</p></div><div><h3>Results</h3><p>There was a female preponderance of the disease (6.5:1) with mean age of disease onset 26.6 years. Isolated ON was the most common presentation at disease onset (60 %). Among motor symptoms at disease onset, only quadriparesis predicted a worse EDSS outcome at last follow up (p = 0.003). Visual acuity ≤6/60 and bilateral involvement was more common in the seropositive patients than in seronegative patients. Anti MOG Antibody was tested in 64.2 % of seronegative patients and was negative. Rituximab was most effective in preventing relapses (no relapses) followed by azathioprine (reduction of ARR of 90.1 %) and mycophenolate (reduction of ARR of 58.6 %). Also the reduction in median EDSS score and median FSS score for vision was greatest for the patients who received rituximab (52.9 % and 33.3 % respectively).</p></div><div><h3>Conclusion</h3><p>Relapsing course of the disease was frequently observed with isolated optic neuritis being the most common symptom at disease onset. Among the motor features only quadriparesis at disease onset predicted a worse disease outcome. Rituximab was most effective in reducing the median EDSS score on follow up and preventing relapse.</p></div>","PeriodicalId":49756,"journal":{"name":"Neurology Psychiatry and Brain Research","volume":"35 ","pages":"Pages 22-28"},"PeriodicalIF":0.0000,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.npbr.2019.12.003","citationCount":"7","resultStr":"{\"title\":\"A study on patients with neuromyelitis optica spectrum disorder from Eastern India\",\"authors\":\"Soumava Mukherjee, Gautam Guha, Manoj Roy, Sinjan Ghosh, Shankar Prasad Saha\",\"doi\":\"10.1016/j.npbr.2019.12.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>To study the clinical presentation and response to immunosuppressives in patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) in a tertiary care hospital of eastern India.</p></div><div><h3>Results</h3><p>There was a female preponderance of the disease (6.5:1) with mean age of disease onset 26.6 years. Isolated ON was the most common presentation at disease onset (60 %). Among motor symptoms at disease onset, only quadriparesis predicted a worse EDSS outcome at last follow up (p = 0.003). Visual acuity ≤6/60 and bilateral involvement was more common in the seropositive patients than in seronegative patients. Anti MOG Antibody was tested in 64.2 % of seronegative patients and was negative. Rituximab was most effective in preventing relapses (no relapses) followed by azathioprine (reduction of ARR of 90.1 %) and mycophenolate (reduction of ARR of 58.6 %). Also the reduction in median EDSS score and median FSS score for vision was greatest for the patients who received rituximab (52.9 % and 33.3 % respectively).</p></div><div><h3>Conclusion</h3><p>Relapsing course of the disease was frequently observed with isolated optic neuritis being the most common symptom at disease onset. Among the motor features only quadriparesis at disease onset predicted a worse disease outcome. Rituximab was most effective in reducing the median EDSS score on follow up and preventing relapse.</p></div>\",\"PeriodicalId\":49756,\"journal\":{\"name\":\"Neurology Psychiatry and Brain Research\",\"volume\":\"35 \",\"pages\":\"Pages 22-28\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.npbr.2019.12.003\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurology Psychiatry and Brain Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0941950019300806\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology Psychiatry and Brain Research","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0941950019300806","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
A study on patients with neuromyelitis optica spectrum disorder from Eastern India
Background
To study the clinical presentation and response to immunosuppressives in patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) in a tertiary care hospital of eastern India.
Results
There was a female preponderance of the disease (6.5:1) with mean age of disease onset 26.6 years. Isolated ON was the most common presentation at disease onset (60 %). Among motor symptoms at disease onset, only quadriparesis predicted a worse EDSS outcome at last follow up (p = 0.003). Visual acuity ≤6/60 and bilateral involvement was more common in the seropositive patients than in seronegative patients. Anti MOG Antibody was tested in 64.2 % of seronegative patients and was negative. Rituximab was most effective in preventing relapses (no relapses) followed by azathioprine (reduction of ARR of 90.1 %) and mycophenolate (reduction of ARR of 58.6 %). Also the reduction in median EDSS score and median FSS score for vision was greatest for the patients who received rituximab (52.9 % and 33.3 % respectively).
Conclusion
Relapsing course of the disease was frequently observed with isolated optic neuritis being the most common symptom at disease onset. Among the motor features only quadriparesis at disease onset predicted a worse disease outcome. Rituximab was most effective in reducing the median EDSS score on follow up and preventing relapse.
期刊介绍:
Neurology, Psychiatry & Brain Research publishes original papers and reviews in
biological psychiatry,
brain research,
neurology,
neuropsychiatry,
neuropsychoimmunology,
psychopathology,
psychotherapy.
The journal has a focus on international and interdisciplinary basic research with clinical relevance. Translational research is particularly appreciated. Authors are allowed to submit their manuscript in their native language as supplemental data to the English version.
Neurology, Psychiatry & Brain Research is related to the oldest German speaking journal in this field, the Centralblatt fur Nervenheilkunde, Psychiatrie und gerichtliche Psychopathologie, founded in 1878. The tradition and idea of previous famous editors (Alois Alzheimer and Kurt Schneider among others) was continued in modernized form with Neurology, Psychiatry & Brain Research. Centralblatt was a journal of broad scope and relevance, now Neurology, Psychiatry & Brain Research represents a journal with translational and interdisciplinary perspective, focusing on clinically oriented research in psychiatry, neurology and neighboring fields of neurosciences and psychology/psychotherapy with a preference for biologically oriented research including basic research. Preference is given for papers from newly emerging fields, like clinical psychoimmunology/neuroimmunology, and ideas.